Background: This study presents real-world evidence on effectiveness of sema OW in a large cohort of T2D patients.

Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 2/1/18 - 4/30/19 (index as first claim). Patients selected had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. All patients and a group of patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and were split into 4 subgroups: GLP-1 naïve, GLP-1 experienced and either group with pre-index A1c >9%.

Results: Of 1,888 patients initiating sema OW, 57.8% were GLP-1 naïve. A1c was significantly reduced in all patients (-0.9%) and subgroups (p<0.001, Figure 1). Persistent patients achieved a 1.1% A1c reduction, with similar or greater reductions across subgroups when compared to all patients. Attainment of A1c <7% increased from 23% pre- to 49% post-index for all patients (20 to 30% pre to post increase in each subgroup, all p<0.001).

Conclusion: Initiation of sema OW was associated with significant reduction in A1c and an increase in reaching A1c <7% regardless of a prior history of GLP-1 use. Sema OW also provides significant change in A1c among patients whose A1c was not controlled on their previous GLP-1.


J. Visaria: None. C. Uzoigwe: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk Inc. Y.M. Paprocki: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk A/S. V. Willey: Employee; Self; HealthCore.


Novo Nordisk

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at